28 Jul 2022 17:32 (1 tahun 2 bulan lalu) -
By Michael Erman (Reuters) - Merck & Co on Thursday reported higher-than-expected second-quarter earnings and revenue on strong sales of its blockbuster cancer drug Keytruda. The company said it earned $4.74 billion in the quarter, or $1.87 a share, compared with $1.55 billion, or 61 cents a share, a year earlier. Analysts on average had expected the company to earn $1.70 a share, according to Refinitiv data. Revenue in the quarter rose 28% from a year ago to $14.6 billion, topping the average Wall Street forecast of $13.9 billion. Much of that beat came from sales of Merck's top-selling drug, the cancer immunotherapy Keytruda, which came ...